Prostatype Genomics / About Prostatype Genomics / Publications

Publications and Posters

Publications

• Fridhammar A, Frisell O, Wahlberg K, Berglund E, Röbeck P, Persson S. Prognostic Testing for Prostate Cancer-A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice. Pharmacoeconomics. 2025 Jan 11. doi: 10.1007/s40273-024-01466-9.
• Saemundsson A, Xu LD, Meisgen F, Cao R, Ahlgren G. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients. Prostate. 2023 Mar 29. doi: 10.1002/pros.24530.
• Röbeck P, Xu L, Ahmed D, Dragomir A, Dahlman P, Häggman M, Ladjevardi S. P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer. Prostate. 2023 Mar 20. doi: 10.1002/pros.24523.
• Söderdahl F, Xu LD, Bring J, Häggman M. A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality. Res Rep Urol. 2022 May 11;14:203-217. doi: 2147/RRU.S358169.
• Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS One. 2016 Jan 5;11(1):e0145545. doi: 1371/journal.pone.0145545.
• Peng Z, Andersson K, Lindholm J, Bodin I, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS One. 2014 Oct 8;9(10):e109610. doi: DOI: 10.1371/journal.pone.0109610
• Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):81-90. doi: 10.1038/pcan.2013.57.

Posters

• Presented at American Urological Association (AUA) 2024 in San Antonio, USA: IMPACT ON PROSTATYPE® P-SCORE ON TREATMENT AND LONG-TERM OUTCOMES IN MEN WITH PROSTATE CANCER. Pontus Röbeck, Emelie Berglund, Anca Dragomir, Michael Häggman and Sam Ladjevardi
• Presented at American Urological Association (AUA) 2022 in New Orleans, USA: P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy.
  Pontus Röbeck, Li-Di Xu2, Dilruba Ahmed, Anca Dragomir, Pär Dahlman, Sam Ladjevardi, Michael Häggman
• Presented at Annual Meeting of Chinese Society of Clinical Oncology (CSCO) 2022 in Xia Men, China: Validation of a three gene signature based-risk score for predicting distant metastasis in Chinese prostate cancer patients––a retrospective pilot study
  Shun Zhang, Junlong Zhuang, Xuefeng Qiu, Yao Fu, Tingting Zhao, Lizhi Yang, Longfei Huang, Li-Di Xu, Hongqian Guo
• Presented at European Association of Urology (EAU) 2020 in Amsterdan, the Netherlands: Can Prostatype test system improve prognostic evaluation for metastasis and death in prostate cancer, a validation study
  Arni Saemundsson, Göran Ahlgren, Florian Meisgen , Rong Cao
• Presented at Urologidagarna 2019 in Västerås Sweden: Prostatype förbättrar prognostisk av metastasering och död i prostatacancer. Arni Saemundsson, Göran Ahlgren, Florian Meisgen and Rong Cao.
• Presented at 33rd Annual EAU Congress 2018 in Copenhagen, Denmark: A novel risk score (P-score) based on a 3-gene signature for survival prognosis of newly diagnosed prostate cancer patients. Peng Z, Chatzianastasio D, Söderdahl F, Honek J, Cao R, Meisgen F, et al. European Urology Supplements 2018;17:e161.
• Presented at American Urological Association (AUA) 2018 in San Fransisco, USA: A novel risk score (p-score) based on a 3-gene signature for estimating risk of prostate cancer specific mortality. Chunde Li, Zhuochun Peng, Dimitris Chatzianastasio, Fabian Söderdahl, Jeffrey Yachnin, and Sten Nilsson. Journal of Urology, 2018. 199(4s):p.e1062-e1062
• Presented at Urologidagarna 2017 in Gothenburg, Sweden: Validering av en prognostisk 3-genssignatur för patienter med nydiagnostiserad prostatacancer. Zhuochun Peng, Jennifer Honek, Rong Cao, Florian Meisgen, Jeffrey Yachnin, Sten Nilsson and Chunde Li.
• Presented at ASCO 2016 in San Diego USA: Validation of a 3-gene signature and development of an authentic cohort database to improve overall survival prediction and clinical treatment decision for patients with newly diagnosed prostate cancer. Chunde Li, Zhuochun Peng, Karl Andersson, Johan Lindholm, Olga Dethlefsen, Yudi Pawitan, Monica Nistér, and Sten Nilsson, Journal of Clinical Oncology, 2016 34:15_suppl, 5047-5047.
• Presented at ESMO 2012 in Vienna, Austria. A prostate cancer expression signature to predict survival benefit of primary hormone therapy. Annals of Oncology, 2012. 23: p.ix299.
• Presented at ESMO 2012 in Vienna, Austria. A prostate cancer expression signature to predict survival benefit of primary hormone therapy. Annals of Oncology. C. Li, Z. Peng, L. Skoog, M. Hjelm-Eriksson, L. Ährlund-Richter, U. Harmenberg, Y. Pawitan, G. Cohn Cedermark, M. Nistér, S. Nilsson, 2012. 23: p.ix299.

Filmed presentations